| Cat. No. | Species | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|
| SI2-H82E3 | Human | Biotinylated Human Siglec-2 / CD22 Protein, His,Avitag™ (MALS verified) |  |
|
|
| CD2-H5253 | Human | Human Siglec-2 / CD22 Protein, Fc Tag (MALS verified) |  |
|
|
| CD2-C52H3 | Canine | Canine CD22 Protein, His Tag |  |
|
|
| CD2-R52H3 | Rat | Rat CD22 Protein, His Tag (MALS verified) |  |
|
|
| SI2-HF2H6 | Human | FITC-Labeled Human Siglec-2 / CD22 Protein, His Tag |  |
|
|
| SI2-H525a | Human | Human Siglec-2 / CD22 Protein, Llama IgG2b Fc Tag, low endotoxin |  |
|
|
| SI2-R52Ha | Rhesus macaque | Rhesus macaque Siglec-2 / CD22 Protein, His Tag |  |
|
|
| SI2-M52Ha | Mouse | Mouse Siglec-2 / CD22 Protein, His Tag |  |
|
|
| SI2-H82F8 | Human | Biotinylated Human Siglec-2 / CD22 Protein, Fc,Avitag™ (MALS verified) |  |
|
|
| CD2-H52H8 | Human | Human Siglec-2 / CD22 Protein, His Tag (MALS verified) |  |
|
|
| SI2-H5228 | Human | Human Siglec-2 / CD22 (176-687) Protein, His Tag |  |
|
|
293 cells were transfected with anti-CD22-scFv and RFP tag. 2e5 of the cells were stained with B. FITC-Labeled Human Siglec-2, His Tag (Cat. No. SI2-HF2H6, 10 µg/mL) and C. FITC-labeled Protein Control. A. Non-transfected 293 cells and C. FITC-labeled Protein Control were used as negative control. RFP was used to evaluate CAR (anti-CD22-scFv) expression and FITC was used to evaluate the binding activity of FITC-Labeled Human Siglec-2, His Tag (Cat. No. SI2-HF2H6) (QC tested).
Anti-Human CD22 MAb (human IgG1) captured on CM5 chip via Anti-Human IgG Fc antibodies surface, can bind Human Siglec-2 (176-687), His Tag (Cat. No. SI2-H5228) with an affinity constant of 11.5 nM as determined in a SPR assay (Biacore T200) (Routinely tested).
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Inotuzumab Ozogamicin | CMC-544; WAY-207294; PF-5208773 | Approved | Pfizer Inc, Ucb | Besponsa | Japan | Precursor Cell Lymphoblastic Leukemia-Lymphoma | s:10:"Pfizer Inc"; | 2017-06-28 | Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma | Details |
| Moxetumomab pasudotox | HA-22; CAT-8015; GCR-8015 | Approved | Astrazeneca Plc | Lumoxiti | EU | Leukemia, Hairy Cell | s:14:"Astrazeneca Ab"; | 2018-09-13 | Leukemia, Hairy Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Prolymphocytic | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| Anti CD22 chimeric antigen receptor T cell therapy (Shanghai Yake Biotechnology) | Phase 2 Clinical | Yake Biotechnology, Beijing Boren Hospital, The First Affiliated Hospital Of Zhejiang University School Of Medicine | Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
| BAY-1862864 | BAY-1862864 | Phase 1 Clinical | Bayer Ag | Lymphoma, Non-Hodgkin | Details |
| Epratuzumab | AMG-412; CDP-3194; IMMU-103; IMMU-1903; IMMU-hLL2 | Phase 3 Clinical | Immunomedics Inc | Lymphoma, B-Cell; Sjogren's Syndrome; Lupus Erythematosus, Systemic; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin | Details |
| CD22 CAR-T Cell Therapy (Hebei Senlang Biotechnology) | Phase 1 Clinical | Hebei Senlang Biological Technology Co Ltd | Sarcoma; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms | Details | |
| CD22-targeted CAR-T cell therapy (PersonGen Biomedicine) | Phase 1 Clinical | Persongen Biotherapeutics | Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Neoplasms, Plasma Cell | Details | |
| Anti-CD19/22-CAR vector-transduced T cell therapy (Chinese PLA General Hospital) | Phase 2 Clinical | People'S Liberation Army General Hospital Military Service | Leukemia; Lymphoma | Details | |
| Anti-CD22/CD19 monoclonal antibody-toxin conjugate | Phase 1 Clinical | Ut Southwestern Medical Center | Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
| UCART-22 | UCART-22 | Phase 1 Clinical | Cellectis | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details |
| Autologous CD19/CD22 chimeric antigen receptor T-cell therapy (MD Anderson Cancer Center) | Phase 2 Clinical | The University Of Texas M.D. Anderson Cancer Center | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details | |
| Anti-CD19 and anti-CD22 CAR T cell therapy (Seattle Children's Hospital) | Phase 1 Clinical | Seattle Children'S Hospital | Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
| Anti-CD19 anti-CD22 bispecific chimeric antigen receptor T cell therapy (Hrain Biotechnology) | Phase 1 Clinical | Hrain Biotechnology | Leukemia, Lymphoid | Details | |
| GTB-1550 | DT-2219; OXS-1550; DT-2219ARL; IND-100780 | Phase 2 Clinical | University Of Minnesota | Leukemia; Lymphoma, B-Cell | Details |
| Anti-CD22 CAR-T cell therapy (iCarTAB BioMed) | Phase 2 Clinical | Icar Bio, China | Lymphoma, B-Cell | Details | |
| Anti-CD22 CAR T cell therapy (Shanghai GeneChem) | Phase 1 Clinical | Shanghai Genechem Co Ltd | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details | |
| CD22-CART | Phase 1 Clinical | Hrain Biotechnology Co Ltd | Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell | Details | |
| TRPH-222 | CD22-4AP; TRPH-222; CAT-02-106 | Phase 1 Clinical | Catalent Inc | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma; Lymphoma, Non-Hodgkin | Details |
| Anti-CD19/CD22 bispecific CAR-T cell therapy (The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine) | Phase 1 Clinical | The Second Affiliated Hospital Of Henan University Of Traditional Chinese Medicine | Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
| 4SCAR-T cell therapy (Shenzhen Geno-Immune Medical Institute) | 4SCAR-T | Phase 2 Clinical | Shenzhen Geno-Immune Medical Institute | Neoplasms | Details |
| Anti-CD22 CAR T cell therapy (Wuhan Bio-Raid) | Phase 1 Clinical | Wuhan Bio-Raid Biotechnology | Lymphoma, B-Cell; Multiple Myeloma | Details | |
| AUTO-3 | AUTO-3 | Phase 2 Clinical | University College London | Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details |
| Dual specificity CD19 and CD20 or CD22 CAR-T cell (Chinese PLA General Hospital) | Phase 2 Clinical | Pla General Hospital | Leukemia; Lymphoma, B-Cell | Details | |
| Anti-CD22-CAR T cell therapy (Kecellitics Biotech) | Phase 2 Clinical | Kecellitics Biotech Company Ltd | Leukemia; Lymphoma | Details | |
| RD-102 | RD-102 | Phase 1 Clinical | Nanjing Iaso Biotherapeutics Co Ltd | Leukemia, Lymphoid; Lymphoma, Large B-Cell, Diffuse | Details |
| Dual anti-CD19/CD22 CAR‐T cell therapy (B-cell malignancies, Stanford University) | Phase 1 Clinical | Stanford University | Lymphoma, B-Cell | Details | |
| JCAR-018 | JCAR-018 | Phase 1 Clinical | National Cancer Institute, Opus Bio | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin | Details |
| CD20/CD22 dual Targeted CAR T-cell therapy (Zhejiang University) | Phase 1 Clinical | Zhejiang University | Hematologic Neoplasms | Details | |
| CART22-cells | CART22-cells | Phase 1 Clinical | Novartis Pharma Ag, University Of Pennsylvania | Leukemia; Lymphoma, B-Cell | Details |
| Anti-CD19/CD22 CAR-T cell therapy (Jiao Tong University) | Phase 1 Clinical | Shanghai Jiaotong University | Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
| Anti-CD19/CD22 chimeric antigen receptor T cell therapy (Nanjing Legend Biotech) | LCAR-L10D | Phase 1 Clinical | Nanjing Legend Biotechnology Co Ltd, Second Affiliated Hospital Xi'An Jiaotong University | Lymphoma, Large B-Cell, Diffuse | Details |
| Anti-CD22 CAR-T cell therapy (No. 307 Hospital) | Phase 2 Clinical | The Fifth Medical Center Of Chinese Pla General Hospital | Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
| CD19/CD20 Dual CAR-T Cell Therapy (China Immunotech) | Phase 1 Clinical | China Immunotech Co Ltd | Lymphoma, Non-Hodgkin | Details | |
| CD19-CD22 CAR-T cells (Shanghai Ultra-T Immune Therapeutics) | Phase 1 Clinical | Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | ||
| CD19/CD22 dual-target CAR-T cell therapy (Shenzhen University General Hospital) | Phase 2 Clinical | Shenzhen University General Hospital | Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
| SM-03 | SM-03; SM-06 | Phase 3 Clinical | Lonn Ryonn Pharma Ltd, Sinomab Bioscience Ltd | Arthritis, Rheumatoid; Lupus Erythematosus, Systemic; Lymphoma, Non-Hodgkin | Details |
| CD19/CD22 bispecific CAR-T (Zhejiang University) | Details |
This web search service is supported by Google Inc.
A-Z